X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Moderna To introduce The Fusion Of COVID-19 And Flu Booster

    September May See Advent of Revised COVID-19 Booster Shots

    First Patient Adopting TAC-001 Has Been Announced By Tallac

    First Patient Adopting TAC-001 Has Been Announced By Tallac

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Continues To Deal With Issues With Expedited Clearance

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

    Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Merck and Orion Announce Global Collaboration for Oncology Drug

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Moderna To introduce The Fusion Of COVID-19 And Flu Booster

    September May See Advent of Revised COVID-19 Booster Shots

    First Patient Adopting TAC-001 Has Been Announced By Tallac

    First Patient Adopting TAC-001 Has Been Announced By Tallac

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Continues To Deal With Issues With Expedited Clearance

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

    Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Merck and Orion Announce Global Collaboration for Oncology Drug

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home IPR Data Management

Data For Treatment of Schizophrenia Disclosed By Cyclerion

Content Team by Content Team
1st August 2022
in IPR Data Management, News
Data For Treatment of Schizophrenia Disclosed By Cyclerion

Positive top-line statistics from Cyclerion Therapeutics’ clinical investigation of CY6463 for the treatment of cognitive impairment associated with schizophrenia have been released. It concerns people with stable schizophrenia who are taking a stable dose of a single atypical antipsychotic drug.

In order to increase endogenous nitric oxide signalling, CY6463 acts as a positive allosteric modulator of soluble guanylate cyclase, a route that has been connected to schizophrenia.

48 individuals with stable schizophrenia participated in the clinical trial. The once-daily CY6463 was safe and well tolerated, with no reports of significant adverse events, severe adverse events, or treatment discontinuation, according to findings from a 14-day, double-blind, placebo-controlled, multiple-ascending-dose study.

In addition, the trial data showed a significant improvement in cognitive function after two weeks of taking 15 mg once a day, as well as a significant improvement in inflammatory biomarkers. The pro-cognitive and anti-inflammatory impacts of CY6463 seen in preclinical research and earlier clinical trials are further supported by these signals on exploratory endpoints.

There is a great need for a therapy option that improves cognition, said the head of the Stanley Center for Psychiatric Research at the Broad Institute, Steven Hyman. Cognitive impairment is a fundamental, debilitating, and untreated, component of schizophrenia. He said he was impressed by the encouraging cognition signals seen in patients with stable schizophrenia after just two weeks of CY6463 dosing. This finding supports the further advancement of CY6463 in conditions marked by cognitive impairment by showing its beneficial effects on inflammation and cognition.

According to chief scientific officer at Cyclerion Therapeutics, Andreas Busch, this is the second clinical study effectively proving safety, pharmacokinetics, and therapeutic effectiveness in a patient population where prior medication development has been exceedingly problematic.

These encouraging results contribute to a substantial body of evidence supporting the development of CY6463 in CNS disorders where cognition is affected, such as CIAS and MELAS. They support earlier clinical and preclinical findings. They are keen to capitalise on the momentum created by this encouraging data and are still looking for ways to speed up development, improve patient selection, and enhance endpoint evaluation.

Previous Post

First Patient Adopting TAC-001 Has Been Announced By Tallac

Next Post

September May See Advent of Revised COVID-19 Booster Shots

Related Posts

Moderna To introduce The Fusion Of COVID-19 And Flu Booster
Drug Development

September May See Advent of Revised COVID-19 Booster Shots

1st August 2022
First Patient Adopting TAC-001 Has Been Announced By Tallac
Clinical Trials

First Patient Adopting TAC-001 Has Been Announced By Tallac

1st August 2022
Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream
FDA Approvals

Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

1st August 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
FDA Approvals

FDA Continues To Deal With Issues With Expedited Clearance

1st August 2022
Test For Sterility of Cell Culture Using Ratio of NA To NAM
Drug Development

Test For Sterility of Cell Culture Using Ratio of NA To NAM

1st August 2022
Authorities Agree To Work Together Towards Integrating RWE
IPR Data Management

Authorities Agree To Work Together Towards Integrating RWE

1st August 2022
Next Post
Moderna To introduce The Fusion Of COVID-19 And Flu Booster

September May See Advent of Revised COVID-19 Booster Shots

Latest News

Moderna To introduce The Fusion Of COVID-19 And Flu Booster
Drug Development

September May See Advent of Revised COVID-19 Booster Shots

1st August 2022
Data For Treatment of Schizophrenia Disclosed By Cyclerion
IPR Data Management

Data For Treatment of Schizophrenia Disclosed By Cyclerion

1st August 2022
First Patient Adopting TAC-001 Has Been Announced By Tallac
Clinical Trials

First Patient Adopting TAC-001 Has Been Announced By Tallac

1st August 2022
Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream
FDA Approvals

Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

1st August 2022
BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
Press Statements

BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology

1st August 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In